This study tests a new drug called ziftomenib for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial includes about 263 participants and aims to find the safest dose and see if the drug can control the disease. It also looks at ho…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC